for people ages 65 years and up (full criteria)
at San Francisco, California
study started
completion around
Principal Investigator
by Yue Leng, PhD
Headshot of Yue Leng
Yue Leng



This study aimed to pilot test a non-pharmacological (behavioral) treatment program targeting improved cognition through improving 24-h sleep-wake cycle in people with mild cognitive impairment (MCI) or mild Alzheimer's disease. A treatment program incorporating bright light therapy and a modified cognitive behavioral therapy for insomnia will be developed to address 24-hour patterns of sleep. We will then pilot test its feasibility and explore its preliminary effects on improving sleep/napping and cognition in patients with MCI or mild Alzheimer's disease.


Sleep, Alzheimer Disease, Cognitive Impairment, Aging, CBT, Cognitive Dysfunction, Sleep intervention


You can join if…

Open to people ages 65 years and up

  • ≥65 years old
  • Memory complaints verified by an informant
  • Clinical diagnosis of mild cognitive impairment (MCI) or mild Alzheimer's Disease
  • General cognitive performance sufficiently persevered such that a diagnosis of Alzheimer's disease cannot be made by the site physician
  • No evidence (CT or MRI scans within 12 months prior to screening) of infection, infarction, or other focal lesions and no clinical symptoms suggestive of intervening neurological disease
  • Adequate visual and auditory acuity to allow neuropsychological testing
  • Meets ICSD-2 criteria for insomnia or circadian rhythm disorders, or shows actigraphy evidence of sleep disturbances and excessive napping

You CAN'T join if...

  • Any major neurologic disease other than suspected incipient Alzheimer's disease, such as Parkinson's disease, multi-infarct dementia, multiple sclerosis, seizure disorder, Huntington's disease, brain tumor or history of significant head trauma
  • Any comorbid psychiatric conditions or severe personality disorder within the past 2 years (by DSM-IV), such as major depression, bipolar disorder, schizophrenia and other psychotic features
  • Any uncontrolled medical conditions or systemic illness that might lead to difficulty complying with the study protocol
  • History of alcohol or substance abuse within the past 2 years
  • Any inadequately treated primary or secondary sleep disorder (due to medical conditions) that might confound the association


  • UCSF accepting new patients
    San Francisco California 94121 United States

Lead Scientist at UCSF

  • Yue Leng, PhD
    As an internationally-trained epidemiologist, Dr. Leng is interested in studying the link between sleep and neurodegeneration in older adults. Her research program, supported by an NIH K99/R00 award, focuses on the relationship between napping, sleep, circadian rhythms and risk of neurodegenerative diseases.


accepting new patients
Start Date
Completion Date
University of California, San Francisco
Study Type
Expecting 40 study participants
Last Updated